Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States.

被引：0
|
作者：
Raval, Amit D.
Chen, Guifang
Korn, Matthew J.
Bernthaler, Andreas
Constantinovici, Niculae
Freedland, Stephen J.
机构：
[1] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[2] Bayer AG, Berlin, Germany
[3] Bayer Consumer Care AG, Basel, Switzerland
[4] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Urol, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.99
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer
    Miyoshi, Yasuhide
    Yoneyama, Shuko
    Kawahara, Takashi
    Hattori, Yusuke
    Teranishi, Jun-ichi
    Ohta, Jun-ichi
    Takebayashi, Shigeo
    Yokomizo, Yumiko
    Hayashi, Narihiko
    Uemura, Hiroji
    UROLOGIA INTERNATIONALIS, 2017, 99 (04) : 400 - 405
  • [32] Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Maw, May Tun Hla
    Malik, Laeeq
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [33] Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
    Marit A. C. Vermunt
    Merel van Nuland
    Lisa T. van der Heijden
    Hilde Rosing
    Jos. H. Beijnen
    Andries M. Bergman
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 785 - 793
  • [34] Real-world biomarker testing patterns in metastatic castration-resistant prostate cancer patients
    Blanc, Simon
    Adeboyeje, Gboyega
    Lee, Liam
    Gart, Mike
    Saunders, William
    Wang, Brandon
    Dave, Poras
    English, Sandy
    Varughese, Prateesh
    Sillah, Arthur
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
    Vermunt, Marit A. C.
    van Nuland, Merel
    van der Heijden, Lisa T.
    Rosing, Hilde
    Beijnen, Jos H.
    Bergman, Andries M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (06) : 785 - 793
  • [36] Real-world treatment patterns in patients diagnosed with metastatic castration-resistant prostate cancer in the US, 2018-2023.
    Efstathiou, Eleni
    Li, Weiyan
    Roose, James
    Kerr, Brendan T.
    Orji, Chinelo
    Yeh, Nina
    Corson, Stephen
    Mukherjee, Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [37] QUALITATIVE EXPLORATION OF THE REAL-WORLD EXPERIENCES OF MEN RECEIVING OR REFUSING CHEMOTHERAPY (DOCETAXEL) FOR THE TREATMENT OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
    Ito, T.
    Grant, L.
    Mills, A.
    Heselwood, A.
    Gater, A.
    VALUE IN HEALTH, 2017, 20 (09) : A450 - A450
  • [38] Treatment guideline concordance for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the United States in IRONMAN, the International Registry for Men with Advanced Prostate Cancer
    McManus, Hannah Dzimitrowicz
    Howard, Lauren
    Crowell, Kerri-Anne
    Hyslop, Terry
    Vinson, Jake
    Rathkopf, Dana E.
    Kantoff, Philip
    Mucci, Lorelei A.
    George, Daniel
    Stopsack, Konrad
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer
    Tashiro, Kojiro
    Kimura, Shoji
    Tsuzuki, Shunsuke
    Urabe, Fumihiko
    Fukuokaya, Wataru
    Mori, Keiichiro
    Aikawa, Koichi
    Murakami, Masaya
    Sasaki, Hiroshi
    Miki, Kenta
    Miki, Jun
    Shimomura, Tatsuya
    Yamada, Hiroki
    Hata, Kenichi
    Nishikawa, Hideomi
    Abe, Hirokazu
    Watanabe, Ken
    Kimura, Takahiro
    CLINICAL GENITOURINARY CANCER, 2024, 22 (03)
  • [40] A real-world registry of patients with metastatic castration-resistant prostate cancer (mCRPC): REMPRO study.
    Gonzalez, Francisco
    Kodagali, Rohit
    Tung, Teresa
    Masoud, Mohamed
    Rajadhyaksha, Viraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345